Target Price | $5.10 |
Price | $0.00 |
Potential |
127,400.00%
register free of charge
|
Number of Estimates | 3 |
3 Analysts have issued a price target T2 Biosystems, Inc. 2026 .
The average T2 Biosystems, Inc. target price is $5.10.
This is
127,400.00%
register free of charge
$5.25
131,150.00%
register free of charge
$5.05
126,150.00%
register free of charge
|
|
A rating was issued by 6 analysts: 0 Analysts recommend T2 Biosystems, Inc. to buy, 3 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the T2 Biosystems, Inc. stock has an average upside potential 2026 of
127,400.00%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 7.19 | 10.81 |
67.77% | 50.38% | |
Net Margin | -696.52% | -548.64% |
149.31% | 21.23% |
3 Analysts have issued a sales forecast T2 Biosystems, Inc. 2024 . The average T2 Biosystems, Inc. sales estimate is
This results in the following potential growth metrics:
3 T2 Biosystems, Inc. Analysts have issued a net profit forecast 2024. The average T2 Biosystems, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -19.19 | -3.16 |
98.46% | 83.53% | |
P/E | 0.00 | |
EV/Sales | 0.92 |
3 Analysts have issued a T2 Biosystems, Inc. forecast for earnings per share. The average T2 Biosystems, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Current | 0.00 | 99.83% |
---|---|---|
2024 |
0.00
100.00%
Unlock
|
T2 Biosystems, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.